Author

D. Rudoy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

A. G. Parrish· 1 shared A. S. Yamashita· 1 shared A. Tsao· 1 shared A. Zhang· 1 shared B. N. Gessesse· 1 shared D. C. Quist· 1 shared D. K. Kumasaka· 1 shared E. C. Holland· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. G. Parrish

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.

S. Schmid, Z. R. Russell, A. S. Yamashita, M. E. West, A. G. Parrish, J. Walker, D. Rudoy, J. Z. Yan, D. C. Quist, B. N. Gessesse, N. Alvinez, P. J. Cimino, D. K. Kumasaka, R. E. Parchment, E. C. Holland, F. Szulzewsky

This study shows ERK signaling promotes resistance to TRK inhibitors in NTRK fusion-driven glioma mouse models and suggests MEK inhibition as a potential combination therapy.

bioRxiv · Mar 13, 2024Cancer Biology

Lethal giant larvae gene family (Llgl1 and Llgl2) functions as a tumor suppressor in mouse skin epidermis

V. M. Bii, D. Rudoy, O. Klezovitch, V. Vasioukhin

This study shows that Llgl1 and Llgl2 function as tumor suppressors in mouse skin epidermis by promoting squamous cell carcinoma development when combined with Trp53 loss.

bioRxiv · Mar 6, 2023 · PreprintCancer Biology

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy

V. Bhatia, N. V. Kamat, T. E. Pariva, L.-T. Wu, A. Tsao, K. Sasaki, L. T. Wiest, A. Zhang, D. Rudoy, R. Gulati, R. A. Patel, M. P. Roudier, L. D. True, M. C. Haffner, P. S. Nelson, , J. K. Lee

This study develops STEAP1 CAR T cell therapy for advanced prostate cancer, showing potent antitumor activity and safety in preclinical models, but also identifies antigen loss as a resistance mechanism.

bioRxiv · May 16, 2022 · PreprintCancer Biology